GAMMA Just Bet $78K on AVTR: Why You Should Too!

Introduction. Avantor, Inc. (NYSE: AVTR) is a life sciences and laboratory supplies company that has recently caught the attention of at least one niche investor. GAMMA Investing LLC – an investment fund – dramatically boosted its stake in Avantor in a recent quarter, increasing its holdings by over 3,400% (to about 60,739 shares) (^[1]). That position was worth roughly $985,000 as of the latest SEC filing (^[1]) (up from only around $36,000 the prior quarter (^[2])). While GAMMA’s dollar bet (approximately $78K added) is relatively small in absolute terms, it signals confidence in Avantor’s prospects. In this report, we dig into Avantor’s fundamentals – from its dividend policy to debt profile, valuation, and risks – to understand why investors might consider following suit. All claims are grounded in first-party filings and credible financial sources.

No Dividend (Yet) – Reinvesting for Growth

Survive the Fed's War on Cash

3 strategies to protect capital from digital money control.

Move an IRA/401(k) into an IRS-approved safe account
No penalties or surprise taxes when done correctly
Preserve purchasing power away from Fed control

Grab the Free Guide

Avantor does not pay a dividend on its common stock, and it has no history of doing so. In fact, the company has “no current plans to pay cash dividends” and intends to retain earnings to fund operations and growth (^[3]). Management explicitly notes that shareholders “may not receive any return on investment unless [they] sell [the] stock at a price greater” than what they paid (^[3]). This policy isn’t likely to change soon. Avantor’s debt agreements restrict it from paying dividends on common stock – essentially all of the firm’s net assets are subject to these covenants (^[3]). The only payouts in recent years were on a now-converted preferred stock (6.25% Series A mandatory convertible), which ended in 2022 (^[3]) (^[3]). For common equity holders, the focus is on capital gains, not income.

Dividend yield is therefore 0%, and will remain so in the near term (^[4]). Instead of dividends, Avantor has funneled cash into debt reduction and strategic initiatives. Notably, the absence of a dividend can be a double-edged sword. On one hand, retaining earnings supports reinvestment in growth opportunities like new products and acquisitions. On the other hand, income-oriented investors might shy away, and the stock’s appeal hinges entirely on business performance and market sentiment. In Avantor’s own words, because it isn’t paying dividends, investors’ only hope for returns is stock price appreciation (^[3]) – placing pressure on management to deliver growth.

Leverage, Debt Maturities, and Coverage

Buffett Alert

Golden Anomaly: One miner big enough for Buffett — selling at a 43% discount to tangible value.

See the name & ticker
✕

Avantor carries a significant debt load, a legacy of leveraged buyouts and acquisitions (such as the 2017 VWR acquisition). As of Q1 2024, the company had about $5.36 billion in total debt (gross) and roughly $5.13 billion in net debt after cash (^[5]). This equated to an adjusted net leverage ratio of ~4.0× EBITDA (^[5]) – meaning net debt is four times the firm’s trailing adjusted EBITDA. In practical terms, Avantor’s interest coverage is adequate but not comfortable: earnings covered interest expense only about 4.3× in 2024 (^[6]). The company’s debt-to-equity ratio stands around 0.5–0.9 (depending on the latest quarter) – moderate for its industry (^[7]) (^[8]). Overall, Avantor is still leveraged, but it has been deleveraging over time. Long-term debt has fallen from nearly $7 billion in 2021 to about $5.3 billion in 2023 (^[9]), and further to ~$3.24 billion (long-term portion) by the end of 2024 (^[9]). (The drop in 2024 reflects both actual debt pay-down and reclassification of a large 2025 maturity into current liabilities.)

Debt maturities appear manageable in the near term. Only a modest portion of debt was due within a year as of early 2024 (about $0.30 billion due in the next 12 months) (^[5]). Avantor faces a larger maturity in late 2025: for example, it has a €500 million 2.625% bond maturing November 2025 (and some term loans), amounting to roughly $0.94 billion due by March 2026 (^[10]). After that, scheduled repayments actually drop off to about $0.52 billion in the following year (^[10]). The bulk of Avantor’s debt (primarily term loans and another Euro-denominated note) matures in 2027–2028 and beyond. This staggered maturity profile gives the company time and flexibility to refinance or pay down debt as needed. In fact, rating agencies have recognized Avantor’s deleveraging progress – Fitch upgraded Avantor’s issuer rating to BB- in 2020 (^[11]), and as of 2025 Avantor Funding’s notes are rated around BB with a positive outlook (^[9]). The bottom line: Avantor’s leverage is high for a non-REIT, but so far it maintains decent coverage and a “balanced and manageable debt maturity profile.”

1,600 / day

Parallel Processing = Trillions

NVIDIA dominates GPUs, but timing matters. We'll tell you when to buy — and which infra & energy plays to watch.

Unlock the Report

NVIDIA: why not now
Coal king: the rebound
SMR Keystone — undiscovered
3 secret partners revealed

Crucially, management is using cash flows to chip away at debt. The company generated $142 million of operating cash in Q1 2024 and $107 million of free cash flow (^[5]) (^[5]). Some of this went toward reducing debt – total debt fell by about $213 million in that quarter (^[5]). Avantor ended Q1 2024 with $235 million in cash on hand (^[5]), which provides a buffer for interest payments or small maturities. It’s worth noting that high leverage limits management’s financial flexibility. Covenants on the credit facilities not only bar dividends but could restrict additional borrowing or investments. Avantor itself warns that its “substantial indebtedness” could pose risks – requiring significant interest payments and potentially “prevent[ing] us from fulfilling our obligations” if business falters (^[3]) (^[3]). Thus far, however, the company has been able to service its debt load, and no near-term liquidity crisis is in sight. Investors should monitor upcoming refinancing plans (e.g. how Avantor handles the 2025 bond maturity) as part of the risk profile.

Valuation: Is Avantor Undervalued?

After a sharp stock price decline over the past year, Avantor’s valuation multiples have compressed to attractive levels. At a share price around $13–14 (recent trading range), the stock trades at roughly 12.5× trailing earnings and only ~12× forward earnings (^[12]). For a life-sciences supplier with steady demand, this earnings multiple is modest – well below the broader market’s P/E and significantly cheaper than large peers. Avantor’s price-to-sales ratio is about 1.3× and its price-to-book ~1.4×, indicating the market values it only slightly above the company’s revenue and accounting equity (^[12]). Perhaps most compelling: Avantor’s enterprise value is only ~8.3× EBITDA (^[13]). An EV/EBITDA near 8 is typically associated with slow-growth or cyclical businesses; by contrast, many larger laboratory and biotech supply peers trade at double-digit EBITDA multiples (for example, Danaher is around ~23× EV/EBITDA) (^[14]). This discount suggests Avantor may be undervalued, if it can stabilize its earnings.

Supporting that view, an activist investor has argued Avantor’s stock is worth much more. In August 2025, Engine Capital (which owns ~3% of AVTR) publicly criticized the company’s performance and proposed exploring a sale (^[15]). Engine’s analysis estimates that a strategic buyer could pay $17–$19 per share for Avantor – well above the ~$12 share price at that time (^[15]). Even without an outright sale, Engine believes operational improvements and a market recovery could lift Avantor’s stock to $22–$26 by 2027 (^[15]). Those implied valuations equate to ~10–12× EBITDA, which is reasonable given Avantor’s industry position. It’s worth noting that analysts are cautious on whether a buyout will occur (citing a lack of obvious buyers) (^[15]). Nonetheless, the activist campaign underscores that sum-of-the-parts and peer comparisons point to significant upside from current trading levels. In short, Avantor’s low valuation reflects past disappointments – but if the company can execute better going forward, there is room for multiple expansion. This asymmetry (limited further downside in multiples, but considerable upside potential) is likely a key reason GAMMA and others have been betting on a rebound.

Of course, valuation alone is not a catalyst. Avantor will need to prove itself by returning to growth. Recent results have been soft: Q1 2024 sales fell 6.3% organically (^[5]) amid weak biopharma demand, and full-year 2023 revenues declined after the pandemic-era surge. The good news is that margins remain healthy (Q1 adjusted EBITDA margin ~16.8% (^[5])) and the company is aggressively cutting costs under a “multi-year transformation initiative” (^[5]). If Avantor can navigate the current slump and resume even mid-single-digit growth, its profits and cash flow should improve – making today’s multiples look plain cheap. In summary, the stock’s current pricing (~$14) seems to factor in a lot of bad news already. Any tangible business turnaround or successful strategic move (e.g. asset sale or merger) could unlock value for shareholders.

Risks, Red Flags, and Open Questions

Despite its upside potential, Avantor is not without risks and red flags. Investors considering “betting” on AVTR should weigh the following issues:

– Sector Slowdown: Avantor’s end markets (biotech, pharma R&D, and academia) have recently softened considerably. In the first half of 2025, the company’s stock price plunged ~45% amid weakened demand from biotech and pharmaceutical customers and reduced government research funding (^[15]). This demand slowdown led management to cut forecasts repeatedly, undermining credibility (^[15]). A key question is whether this is a temporary, post-pandemic correction or a longer-term stagnation. If biotech funding and lab activity remain weak, Avantor’s growth could stall further.

– Execution and Oversight Issues: An activist has flagged concerns about Avantor’s operational execution and governance. Engine Capital’s letter in 2025 cited “repeated forecast cuts and poor operational oversight” by the board (^[15]). Indeed, Avantor expanded rapidly via acquisitions, and it carries nearly $7 billion of goodwill and intangibles on its books (a sign that past deals have yet to fully pay off). The heavy use of “adjusted” earnings (excluding amortization and one-time charges) is a red flag – GAAP EPS was only $0.52 in 2023 (^[4]), roughly half of the adjusted EPS. Management must rebuild investor trust by delivering consistent results and better integrating past acquisitions.

– High Leverage & Interest Rate Risk: Although improving, Avantor’s leveraged balance sheet remains a risk. Net debt is about 4× EBITDA, and even at lower interest rates the company paid roughly $200–300 million in interest annually (implying interest eats up a sizable share of operating profit). As interest rates have risen, Avantor’s floating-rate debt (e.g. term loans) becomes costlier. The firm’s interest coverage of ~4× (^[6]) could deteriorate if EBITDA falls or interest costs climb, potentially pressuring its credit ratings. High debt also limits strategic flexibility – for instance, Avantor cannot easily make large acquisitions or return cash to shareholders while deleveraging is a priority. Any misstep in execution could be magnified by the leverage.

– Limited Shareholder Returns (No Dividend, No Buybacks): Unlike some stable peers, Avantor offers no dividend and has not been repurchasing stock. Excess cash is earmarked for debt reduction. This means investors won’t get paid to wait. The company explicitly warns that without dividends, shareholders will see no return unless the stock price rises (^[3]). If the turnaround takes longer than expected, holding AVTR could be an unproductive use of capital compared to dividend-paying alternatives.

– New CEO and Strategic Uncertainty: Avantor is undergoing a leadership change at a critical time. Longtime CEO Michael Stubblefield resigned in 2025, and the board appointed Emmanuel Ligner (formerly of Cytiva/GE Life Sciences) as the new CEO effective August 18, 2025 (^[15]). Ligner’s fresh perspective could drive positive change – indeed, the stock jumped ~8% on the announcement of his hiring (^[15]). However, leadership transitions carry uncertainty. It remains to be seen what strategic pivots or restructuring he may pursue. Will Avantor focus on organic growth, make divestitures, or even entertain a sale of the company? The activist push for a potential sale adds another wildcard: while Engine Capital sees a buyout as value-creating (^[15]), analysts are skeptical about finding a willing acquirer (^[15]). The outcome of this strategic tug-of-war is an open question.

– Macroeconomic and Other Risks: As a global supplier, Avantor faces typical macro risks – inflation in raw material costs, supply chain disruptions, and currency fluctuations (about one-third of sales are international). The company also has environmental and legal exposures (handling chemicals and reagents can bring liability). These have not featured prominently in recent filings, but any unexpected expense (e.g. a large environmental remediation or lawsuit) could hit cash flow when debt levels are high (^[3]). Lastly, competition from larger players (Thermo Fisher, Merck KGaA, etc.) and emerging low-cost rivals means Avantor must keep innovating and differentiating its offerings to maintain margins.

Open questions for investors include: How quickly will biopharma demand recover? Can the new CEO execute on cost cuts and reignite growth? Will Avantor consider breaking up or selling a division to unlock value? There’s also the matter of what happens when that November 2025 bond comes due – refinancing is likely, but at what interest rate? These uncertainties mean that, while Avantor’s stock is cheap, patience and a bit of faith in the turnaround are required.

Conclusion

GAMMA’s $78K wager on Avantor may be tiny, but it shines a light on a beaten-down company with significant rebound potential. In summary, Avantor offers a unique mix of pros and cons: on one hand, no dividend and high debt, but on the other hand a vital niche in life-science supply, solid cash flows, and a stock valuation that prices in a lot of bad news. The company’s priority is clearly on strengthening its balance sheet and operating efficiency rather than shareholder payouts – a strategy that could pay off through equity appreciation if earnings improve. For investors with a bit of risk tolerance, the situation sets up a classic turnaround thesis: buy a quality business at a cyclical low, with the expectation of a recovery.

That said, due diligence is key. Avantor’s fundamentals are sound enough – recurring revenues, decent margins, and manageable debt maturities – but the firm must navigate near-term headwinds. Keep an eye on upcoming earnings for signs of stabilization in biopharma orders, and watch how the new leadership addresses the activist pressure. If Avantor can even approach its pre-slowdown growth trajectory, today’s valuation will look overly pessimistic in hindsight. In that case, those who “bet” on AVTR at these levels (like GAMMA did) may indeed be rewarded. As always, however, risks abound – so any investment should be sized appropriately. In conclusion, **Avantor represents an intriguing value-plus-growth opportunity**: a stock with bargain multiples and an improving story. GAMMA’s move suggests confidence, and after examining the data, one can see why investors might consider following suit – albeit with eyes open to the challenges ahead. (^[15]) (^[15])

Sources

For informational purposes only; not investment advice.